Case Report: Immune Checkpoint Inhibitor-Induced Exuberant Tumor Inflammation With Accelerated Clinical Deterioration in Metastatic Renal Cell Carcinoma

Case Report: Immune Checkpoint Inhibitor-Induced Exuberant Tumor Inflammation With Accelerated Clinical Deterioration in Metastatic Renal Cell Carcinoma

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. Nivolumab, an anti-PD-1 monoclonal antibody, markedly improved overall survival in advanced renal cell carcinoma (RCC). However, ICIs can rarely trigger massive inflammation, a phenomenon characterized by rapid acceleration in r...

Full description

Bibliographic Details
Main Authors: Dharmesh Gopalakrishnan, Rohit K. Jain, Laurie Herbst, Marcus Sikorski, Silpa Mandava, Gissou Azabdaftari, Bo Xu, Charles LeVea, Kevin Robillard, Marc S. Ernstoff, Saby George
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
renal-cell carcinoma
immune checkpoint inhibitor
tumor inflammation
nivolumab
pseudoprogression
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.679177/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.679177/full

Similar Items